EarningsQ4 2026 Earnings Report
MX:RMD Q4 2026 EPS Results
Actual EPS$53.63
Consensus EPS$52.59
Beat/MissBeat by +$1.04
One Year Ago EPS$46.35
MX:RMD Q4 2026 Revenue Results
Actual Revenue$26.61B
Expected Revenue$26.56B
Beat/MissBeat by +$42.56M
YoY Revenue Growth+8.58%
Earnings Announcement Details
QuarterQ4 2026
Date08/06/2026
TimeAfter Close
Conference CallThursday, August 6, 2026
MX:RMD Upcoming Earnings
Resmed's next earnings date is estimated for October 29, 2026, based on past reporting schedules.
Q4 2026 Earnings Call Audio
MX:RMD Q4 2026 Earnings Call
0:00 / 0:00
Q4 2026 Earnings Slide Deck
Q4 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed solid underlying growth and margin expansion across the core sleep business, strong full-year cash generation, material shareholder returns, and continued product and software momentum (masks, AirSense/AirCurve rollouts, GenAI MyAir, Oura partnership). Key negatives were a sizeable Astral field-safety provision and the suspension of Astral sales (driving significant ventilator revenue declines and near-term revenue/EPS headwinds), higher near-term R&D and SG&A investment, and Q4 free cash flow compression. Management provided explicit FY2027 revenue and EPS guidance, actions to return capital, and plans to prioritize high-ROI investments while actively managing the portfolio—presenting a constructive execution path despite the discrete Astral-related disruption.Company Guidance
Q4 Revenue and EPS Growth
Group revenue of $1.5B in Q4, +9% headline and +8% constant-currency; non-GAAP EPS of $2.95 in Q4, +16% year-over-year.
Strong Full-Year Financial Performance
Fiscal 2026 revenue +10% (headline) and +8% (constant-currency); non-GAAP EPS +17% for the year; full-year free cash flow of >$1.6B.
Gross Margin and Operating Leverage
Non-GAAP gross margin in Q4 was 62.3%, up 90 basis points year-over-year; management cited ~290 basis points of gross margin expansion for the year and 180 basis points of operating margin expansion for FY2026.
Capital Return to Shareholders
Returned >$1B to shareholders in FY2026 (72% increase vs prior year); FY2027 plans to return well north of $1.5B and announced dividend increase of 10% to $0.66/quarter and $1.85B+ total capital return guidance.
Product, Mask and Software Momentum
Global rollout and continued adoption of AirSense 11 and AirCurve 11 platforms; strong uptake of AirTouch N30i and AirFit F40 masks; AirTouch N30i drives 6% higher 90-day compliance vs silicone equivalent; MyAir GenAI coach >1.5M inquiries to date reducing service volume.
Strategic M&A and Portfolio Actions
Closed Noctrix acquisition (Nydro for RLS) on June 1; integrating VirtuOx; announced divestiture of MatrixCare to sharpen focus on core growth areas and improve RCS growth/profitability.
Demand-Generation Opportunities
Early success with consumer partnerships (Oura drove ~13,000 users to ResMed.com; thousands took assessments with ~75% of assessed users previously undiagnosed) and data showing GLP-1 patients ~11% more likely to start PAP and higher multi-year resupply rates (3% at 1 year, 6% at 3 years).
Operational Productivity
Supply chain productivity and efficiencies offset inflationary pressure year-over-year, enabling margin expansion; Q4 free cash flow of $404M and cash balance ~ $1.5B at quarter end.
MX:RMD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed